IGC Pharma (IGC) Registration Filing summary

Company overview and business model

• Clinical-stage pharmaceutical company focused on developing innovative treatments for Alzheimer's disease, metabolic disorders, and related neurodegenerative conditions, leveraging AI for drug discovery and early diagnosis.

• Lead candidate IGC-AD1 targets agitation in Alzheimer's dementia and is in Phase 2 clinical trials; pipeline includes early-stage therapies and AI-powered diagnostic models.

• Strategy centers on addressing both symptomatic and disease-modifying mechanisms to create sustainable value for patients, caregivers, and shareholders.

Financial performance and metrics

• As of October 30, 2025, 92,868,241 shares of common stock were outstanding, with 8,683,998 stock awards granted (subject to vesting), 13,550,000 shares reserved for stock options, and approximately 1 million shares reserved for future issuance.

Use of proceeds and capital allocation

• No proceeds will be received from this offering; all shares are being sold by selling stockholders.

• Company will bear all costs, expenses, and fees related to the registration of the securities.